Document is current
Any future updates will be listed below
-
Authors
Paschou, Stavroula A. https://orcid.org/0000-0002-0651-1376
Athanasiadou, Kleoniki I. https://orcid.org/0000-0002-0811-8156
Papanas, Nikolaos https://orcid.org/0000-0002-7320-785X
- License Information
-
More Information
Article History
Received: 7 January 2024
Accepted: 31 January 2024
First Online: 16 February 2024
Declarations
:
: Nikolaos Papanas is a member of the Editorial Board for Diabetes Therapy. Nikolaos Papanas was not involved in the selection for peer reviewers for the manuscript, not any of the subsequent editorial decisions. Stavroula A. Paschou has participated in clinical trials sponsored by Novo Nordisk, Sanofi, and Eli Lilly, and has received honoraria for advisory board membership or lectures from Novo Nordisk, Sanofi, Bausch Health, and Abbott. Kleoniki I. Athanasiadou has no conflict of interest. Nikolaos Papanas has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer, and Sanofi-Aventis.
: This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
